Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. (Sisonke Boost)
Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boostof Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)
Sponsor: Bio Analytical Research Corporation
Listed as NCT05148845, this PHASE3 trial focuses on SARS CoV 2 Infection and remains ongoing. Sponsored by Bio Analytical Research Corporation, it has been updated 7 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Sep 2022 — Jan 2024 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — May 2022 [monthly]
Recruiting PHASE3
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bio Analytical Research Corporation
- BioVac
- Biocair
- Clinical Laboratory Services
- Dis-Chem Pharmacy
- Fred Hutchinson Cancer Center
- Hutchinson Center Research Institute of South Africa (HCRISA)
- Institute of Infectious Disease and Molecular Medicine
- Janssen Vaccines & Prevention B.V.
- KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP
- National Department of Health of South Africa
- National Institute of Communicable Diseases - NICD
- Right to Care
- Wits Health Consortium (Pty) Ltd
For direct contact, visit the study record on ClinicalTrials.gov .